PEOPLE

Dr. Gloude brings skills, expertise in pediatric BMT

Nicholas Gloude, M.D., recently joined the Division of Hematology/Oncology at Rady Children’s Hospital-San Diego. He is a member of the Blood and Bone Marrow Transplantation Program and is also an assistant clinical professor of pediatrics at UC San Diego School of Medicine.

Dr. Gloude has clinical and research interests in pediatric leukemia and lymphoma, bone marrow failure and bone marrow transplantation. He is a member of the Hospital’s Bone Marrow Transplant Steering and Selection committees and serves on the Scientific Organizing Committee for the 2018 American Society of Blood and Marrow Transplantation’s Annual Tandem Meeting. His professional society memberships include the American Society for Blood and Marrow Transplantation, American Society of Pediatric Hematology Oncology and the Children’s Oncology Group.

Among his awards, Dr. Gloude was honored in 2017 with the top abstract at the 11th Annual Thomas F. Boat Lecture Series for “Neutrophil Extracellular Traps, Endothelial Injury, and Complement Activation in Thrombotic Microangiopathy and Graft Versus Host Disease.” He also received the Pediatric Blood and Marrow Transplant Consortium Young Investigator Travel Award and an American Society of Blood and Marrow Transplantation Travel Grant. In 2016, he garnered the UC San Diego Department of Pediatrics and Rady Children’s Hospital Best in Class – Pediatric Fellow INQUIRY Award. Additionally, along with one of his attending physicians, he received the ASPHO (American Society of Pediatric Hematology/Oncology) Clinician Educator Award.

Dr. Gloude attended medical school at Rush University in Chicago and completed his pediatric residency at CHOC Children’s (Children’s Hospital of Orange County). He then completed a fellowship in pediatric hematology/oncology at UC San Diego, followed by additional training in pediatric bone marrow transplantation at Cincinnati Children’s Hospital.

PROGRAMS

Fourth-year fellowships offered in
two subspecialties

Rady Children’s Division of Hematology/Oncology, through UC San Diego School of Medicine, offers two fourth-year fellowships: one in pediatric neuro-oncology and one in pediatric hemostasis and thrombosis.

The Neuro-Oncology Fellowship, directed by John Crawford, M.D., M.S., offers extensive inpatient and outpatient clinical training as well as rotations in neurosurgery, neuropathology, radiation oncology and neuroradiology. The current Neuro-Oncology fellow is Hamza Gorsi, M.D., who completed his pediatric hematology-oncology fellowship at Brown University.

The fellow plays a major role in the assessment and ongoing management of patients referred for second opinion consultation to Rady Children’s Proton Therapy Program. Additionally, one month is spent in the Adult Neuro-Oncology Program at the UC San Diego Moores Cancer Center, where clinical experiences and combined pediatric-adult neuro-oncology clinical conferences help prepare the fellow to provide continuity of care into adulthood. The fellow attends weekly multidisciplinary clinical rounds, tumor boards and translational research conferences with faculty members at the Moores Cancer Center and Sanford Burnham Prebys Medical Discovery Institute. A clinical research project is also part of the training.

The Hemostasis and Thrombosis Fellowship provides in-depth inpatient and outpatient pediatric hemostasis and thrombosis clinical training as well as rotations in hematology, transfusion services, adult hemophilia care and coagulation testing. The current Hemostasis and Thrombosis fellow is Fadi Nossair, M.D., who completed his pediatric hematology-oncology fellowship at CHOC Children’s (Children’s Hospital of Orange County), through the University of California, Irvine.

The fellow plays a leading role in the assessment and ongoing management of children and adolescents (0-21 years of age) with inherited and acquired bleeding and clotting disorders. Along with attending didactic conferences and weekly multidisciplinary hemophilia clinic rounds, the fellow participates in the Venous Thromboembolism Prevention Committee, the Hemophilia Quality Improvement Committee and the hospital-wide Transition Committee. The fellow engages in clinical research and quality improvement projects under the mentorship of Courtney Thornburg, M.D., M.S.
Integrative medicine program garners national award

The Hematology/Oncology division’s Integrative Medicine Program received a $50,000 Hyundai Impact Award, which will be used to fund the work of program coordinator Jeanie Spies, M.S.N., P.N.P. The program aims to improve quality of life and minimize the side effects associated with cancer treatment.

Patients are offered a wide range of therapies, including acupuncture, aromatherapy, art therapy, massage and healing touch, as well as a chronic pain program. Weekly yoga classes and monthly cooking classes are also provided at Hospital. Along with the therapy providers, the team includes a case manager, psychologist and clinical dietitians.

Rady Children's is one of 25 recipients of the award, which is given to pediatric oncology departments at select children's hospitals nationwide. Hyundai representatives came to the Hospital to present the award to Spies, along with a special lab coat. A handprint ceremony followed, in which cancer patients dipped their hands in paint and placed their handprints on a white 2017 Hyundai Santa Fe. These colorful handprints are meant to represent the children’s journeys, hopes and dreams.

With this award, Hyundai Hope On Wheels has given more than $1.3 million to Rady Children's to help cancer patients.

INNOVATIONS

Rady Children’s to be certified as CAR T-cell treatment center

Rady Children's Hospital will be one of 32 certified treatment centers to provide the first Food and Drug Administration-approved chimeric antigen receptor (CAR) T-cell treatment to cancer patients. The gene therapy uses modified versions of a patient’s own blood cells to target and destroy cancer cells.

Tisagenlecleucel (Kymriah) is specifically approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that
is refractory or in second or later relapse, based on phase II results from the international ELIANA trial; the overall remission rate within three months of treatment was 83 percent.

Approximately 3,100 patients age 20 and younger are diagnosed with ALL each year, according to the National Cancer Institute. In an estimated 15-20 percent of patients, the cancer has not responded to or has returned after initial treatment.

The therapy will be used by Rady Children’s Blood and Bone Marrow Transplantation Program, Deborah Schiff, M.D., a member of this team and a clinical professor of pediatrics at UC San Diego School of Medicine, will oversee the treatment.

Tisagenlecleucel does present a risk of serious, potentially life-threatening side effects, which include high fever, flu-like symptoms, infections and low blood pressure. The FDA requires special certification for all sites offering the treatment to confirm that the institution is qualified to handle serious adverse reactions, should they occur.